Lv11
10 积分 2024-12-10 加入
OA09.06 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC
2小时前
已完结
Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy
2小时前
已完结
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer
10个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
10个月前
已完结
NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows
10个月前
已完结
NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry
10个月前
已关闭
Characterization of NRG1 gene fusion events in solid tumors
10个月前
已关闭
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
10个月前
已完结
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
10个月前
已完结
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
10个月前
已完结
皖公网安备34019202002308
